ROLE OF CHLORAMBUCIL IN COMBINATION OR NOT WITH ANTI‐CD20 AS FRONTLINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA IN "REAL LIFE"
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.49_2631
Abstract: CLL/SLL pts. Most surprisingly is the high rate of infusion related reactions; however, these were mainly confined to grade 2 reactions and grade 3 reactions were much lower than in the CLL11 trial (Goede V,… read more here.
Keywords: therapy; anti cd20; cd20 frontline; combination anti ... See more keywords
Optimal combination of anti-inflammatory components from Chinese medicinal formula Liang-Ge-San.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of ethnopharmacology"
DOI: 10.1016/j.jep.2020.113747
Abstract: ETHNOPHARMACOLOGICAL RELEVANCE Liang-Ge-San (LGS), a traditional Chinese medicine (TCM) formula, is usually used in acute inflammatory diseases in China. AIM OF THE STUDY This study aims to detect the optimal combination of anti-inflammatory components from… read more here.
Keywords: anti inflammatory; combination; optimal combination; liang san ... See more keywords
Unique combination of anti‐paraneoplastic antigen Ma2 antibody‐positive Ophelia syndrome and opsoclonus‐myoclonus syndrome in an adult Hodgkin’s lymphoma patient
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Neuroimmunology"
DOI: 10.1111/cen3.12549
Abstract: Paraneoplastic neurological syndromes are a rare presentation of malignant lymphomas at diagnosis or relapse. The most frequent form is the cerebellar degeneration associated with Hodgkin’s lymphoma (HL), but several other syndromes, such as limbic encephalitis,… read more here.
Keywords: unique combination; lymphoma; paraneoplastic antigen; hodgkin lymphoma ... See more keywords
Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Gut"
DOI: 10.1136/gutjnl-2019-320116
Abstract: We read with great interest the article by Gerbes et al, 1 which indicated the prospects of immune-based therapies in hepatocellular carcinoma (HCC) and that by Zhu et al, 2 which proposed their new strategy… read more here.
Keywords: hepatocellular carcinoma; combination; vegf agents; hcc ... See more keywords
Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1724
Abstract: Niraparib is an orally available and selective poly(ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response… read more here.
Keywords: combination; niraparib treatment; treatment; preclinical models ... See more keywords
Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2790
Abstract: TGFβ may act as a tumor suppressor early in tumorigenesis; however, TGFβ is also known to support tumor growth via multiple mechanisms, including promotion of epithelial-mesenchymal transition, fibroblast recruitment, ECM deposition, neovascularization, and immunosuppression of… read more here.
Keywords: anti pd1; sar439459; tgf; combination anti ... See more keywords
Abstract 4547: Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4547
Abstract: Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor involved in maintaining immunological tolerance via regulation of T-cell activation, proliferation and response. Ligand-mediated activation of LAG-3 negatively regulates T-cell activity that is thought to actively contribute… read more here.
Keywords: combination anti; monotherapy combination; lag; antibody ... See more keywords
Abstract 4263: Anti-Siglec 7 antibody displays potent anti-tumor immunity and demonstrates improved tumor control in combination with anti-PD1 in ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4263
Abstract: High grade serous ovarian cancer (OC) and ovarian carcinosarcoma, referred as “Cold” tumors have restricted treatment choices and being associated with high mortality. Current immune checkpoint inhibitors (CPIs) have had modest impact for OC treatment;… read more here.
Keywords: anti pd1; combination anti; tumor; cancer ... See more keywords
Abstract 5492: Determining effects of the CD206 positive M2 macrophage depleting engineered exosome in combination with anti PD1 therapy in breast tumor
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5492
Abstract: Introduction: Triple negative breast cancer (TNBC) subtype of breast cancer, which lacks molecular markers such as HER2 and estrogen/progesterone receptors, has limited treatment options. Exosomes are nano-sized (30-150 nm) spherical vesicles, derived from the endosomal… read more here.
Keywords: positive macrophage; cd206 positive; anti pd1; breast ... See more keywords
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine to suppress tumor growth and metastasis in HPV-infected cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e23175
Abstract: e23175Background: PD-1/PD-L1 immunotherapy is viewed as having clinical benefits in advanced cancers but is effective in only a few patients, suggesting that an efficient combination approach is needed to improve efficacy for certain non-small cell… read more here.
Keywords: combination anti; anti mab; mab plus; llo vaccine ... See more keywords
Phase 1-2 study of TI-061 alone and in combination with other anti-cancer agents in patients with advanced malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps3109
Abstract: TPS3109Background: The cell surface protein CD47 is expressed or over-expressed on many tumor types. CD47 binds to signal regulatory protein alpha (SIRPα) on macrophages resulting in a “don’t eat m... read more here.
Keywords: alone combination; anti cancer; combination anti; phase study ... See more keywords